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The CXCR1 Axis: A putative therapeutic cancer stem cell-like 
marker in pancreatic ductal adenocarcinoma
Preliminary Results
▪ Increased expression of CSC-like cell markers in GemR cell lines
▪ Increased expression of CSC-like cell markers in both parent and GemR cell lines when treated 
with gemcitabine
▪ Decreased expression of CSC-like cell markers when treated with navarixin
▪ Heightened CXCL8 mRNA and protein expression within parent and GemR CD18 cells when 
treated with gemcitabine or navarixin.
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Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest survival rates of all cancers in the 
United States. Not only is PDAC found at the late stages, but patients also present with or develop 
chemotherapy resistance at an elevated frequency. Left with limited options for treatment, researchers are 
investigating new options for these patients. One major area of interest is the sub-population of cells in the 
tumor called cancer stem cells (CSCs). These cells are known for having high resistance to chemotherapy, 
along with propagating and re-building the tumor after most non-CSCs have been therapeutically targeted. 
Previous studies have determined CXCR4, ALDH1, CD24, CD44, and CD133 as markers for CSC-like 
PDAC cells. In the present study, we investigate the closely related CXCR1 as another possible marker and 
therapeutic target for PDAC CSCs. CXCR1 is known for its role in inflammation and wound healing. The 
CXCR1 axis includes the ligands CXCL6 and IL-8, both of which promote the progression of cancer. 
Previously, Ginesteir et al. has shown targeting the CXCR1 axis in triple negative breast cancer reduced 
CSC-like phenotypes in vitro and in vivo. Investigations of CXCR1 in PDAC demonstrate IL-8 induces 
increased tumorsphere formation in vitro (Chen et al.), leading us to investigating CXCR1 in PDAC CSCs. 
We hypothesize that PDAC cells with high CXCR1 activity also exhibit increased CSC-like characteristics 
and targeting CXCR1 will reduce those characteristics.
To investigate the role of CXCR1 in CSC-like phenotype of PDAC, we used the PDAC cell line CD18, 
along with its gemcitabine resistant (GemR) counterpart. We used the CXCR1/2 antagonist Navarixin at 
high enough concentrations to inhibit CXCR1. Using the previously found gemcitabine and navarixin IC50 
concentrations for each parent cell line, we treated cells for 72 hours. Post-treatment, we analyzed the 
expression of several known CSC markers, CXCR1, and IL-8 through qRT-PCR and ELISA. We expected to 
see higher expression and activity of CXCR1 in cells with higher known CSC marker expression. We also 
anticipated that gemcitabine treatment would induce higher expression of CSC markers, whereas navarixin
would exhibit lower expression. From our results, we see the beginning trends of gemcitabine treated cells 
having increased expression of the CSC markers and navarixin decreasing or not changing the expression 
levels. These results differ for IL-8, which undergoes an increase in expression when treated with both 
gemcitabine and navarixin, which may warrant further exploration into the role of ligands in CSC-like 
phenotypes. One possible explanation for this difference would be the regulation of IL-8 expression based 





We will continue to explore the impacts of gemcitabine and navarixin on CSC-like 
cell markers through repetition of these experiments in order to compare results and 
formulate more definitive data. At this point in time, some of the results are not clear 
enough to draw a thorough conclusion. Once this is done, we will study the tumorsphere
formation capabilities of untreated cells expressing high CXCR1 levels as another 
means of determining the CSC-like properties of CXCR1-high cells.
Moving forwards, it would also be beneficial to look into potential causes behind the 
occasional increases in CSC-like cell marker expression when treated with navarixin and 
decrease in CD24 expression in the GemR cell line as compared to the parent cell line. 
Figure 6. CXCL8 concentration does not vary significantly between parent CD18 and CD18 
GemR cell lines (p>0.9999).
Introduction
PDAC is a highly deadly disease, with a 5-year survival rate of less than 10% of patients. One of the 
prominent causes of this low expectancy is resistance to a common treatment for PDAC, chemotherapy. 
One potential factor contributing to resistance is the presence of cells that exhibit cancer stem cell-like 
(CSC-like) properties within the tumor. These CSCs, like other stem cells, have the ability to self-renew and 
propagate, as well as differentiate into the variety of cells that make up the overall heterogeneous tumor 
(Figure 1A). CSCs also have the ability to enter and exit a quiescent state in which they aren’t actively 
metabolizing high levels of proteins or dividing. Though the metabolic properties of these quiescent cells 
are limited, they express ALDH1 at a higher rate, which serves to convert toxic drugs into less toxic forms 
(Lee et al. 2018). Alongside ALDH1, CD24, CD44, CD133, and CXCR4 are published markers for cells with 
CSC-like properties. Another receptor suspected to play a role in CSC activity is the chemokine receptor 
CXCR1. In a normally functioning cell, the CXCR1 pathway promotes inflammatory responses and wound 
healing. In cancerous cells, where the pathway is not properly regulated, CXCR1 interacts with its ligands, 
CXCL6 and IL-8, to promote proliferation and metastasis of the tumor, as well as increase angiogenesis 
and chemotherapy resistance (Figure 1B). Previously published studies report targeting CXCR1 in triple 
negative breast cancer decreases the CSC-like cells both in vitro and in vivo (Ginesteir et al). In PDAC, 
Chen et al. treated tumor cells with exogenous IL-8 and found it has the capacity to induce tumorsphere
formation in vitro.
Based on this background, it was hypothesized that targeting the CXCR1 pathway using the inhibitor 
drug Navarixin would negatively impact the CSC population within PDAC cells, as well as reducing the 
population of cells resistant to chemotherapy.
Figure 1. A. Cancer stem cell theory proposes that tumor cells originate and differentiate from a 
parent cancer stem cell. B. CXCR1 interacts with CXCL6 and IL-8 to promote various functions 
adverse to patient survival in cancerous tumors.
StrategyExperimental Strategy
Figure 2. Outlines the 
generation of cell lines 
cultured with gemcitabine 
and navarixin for CXCR1 
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IL-8 Content in Parent and GemR Lines
Figure 6. The expression of IL-8 by CD18 and the derived CD18 GemR cell lines. A. 
Relative expression of IL-8 from isolated mRNA. B. Protein expression of IL-8 as 























































































IL-8 Content Modulation by Gemcitabine and 
Navarixin
Figure 7. A-D. Changes in IL-8 mRNA and protein expression in parent and GemR CD18 
cells when treated with gemcitabine for 72 hours. mRNA expression was measured via 
qRT-PCR, protein expression was measured by ELISA and normalized to protein content. 
E-H. mRNA and protein expression in cells treated with navarixin for 72 hours. An overall 
increase in both mRNA and protein expression is observed for both treatments. *p<0.05 
**p<0.01 ***p<0.001





























































































































































































































































































A.                  B. C. D.
CSC Marker Expression in Parent and GemR Lines
Figure 3. Expression of CXCR1, CD24, 
and CD44 in parent CD18 and derived 
CD18 GemR cell lines. A general increase 
in expression is observed from parent to 
GemR cell lines for both CXCR1 and CD44, 
while expression of CD24 decreases. 
*p<0.05 **p<0.01 ***p<0.001







































































































Regulation of CSC Marker Expression by Gemcitabine
Figure 4. Expression of CXCR1 and CSC markers in parent and GemR cell lines when treated with gemcitabine 
for 72 hours. A significant increase in the expression of each marker is observed when the cells are treated with 






































































































































































































CSC Marker Expression Inhibited by Navarixin
Figure 5. CXCR1 and CSC marker expression in parent CD18 and derived CD18 GemR cell lines when treated for 72 hours 
with Navarixin.CXCR1 expression experiences a general increase in the presence of navarixin, while CD24 expression 
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